Tisotumab vedotin plus carboplatin or pembrolizumab in recurrent or metastatic cervical cancer: 5-year results from the innovaTV 205/ENGOT-cx8/GOG-3024 study

Els Van Nieuwenhuysen, Ignace Vergote, Leslie M. Randall, Jacqueline Tromp, Domenica Lorusso, Roisin E. O’Cearbhaill, Ingrid Boere, Carmela Pisano, Luis Manso Sanchez, Susana Banerjee, Dearbhaile C. Collins, Michal Zikán, Cara Mathews, Jan Kümmel, Bohuslav Melichar, Amanda L. Jackson, Kristine Madsen, Christine Gennigens, Nelleke Ottevanger, Sharad Ghamande, Vanda Salutari, Jean-Francois Baurain, Anna K.L. Reyners, Michael Chisamore, Umberto Conte, Kristian Windfeld, Melissa Geiger, Henrik Hansen, Hannelore Denys, David Cibula, Ana Oaknin, Toon Van Gorp, Bradley J. Monk

Open source

DOI: 10.1016/j.ygyno.2026.02.008
Published: 2026-04
Container: Gynecologic Oncology
Publisher: Elsevier BV
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.ygyno.2026.02.008,
  title = {Tisotumab vedotin plus carboplatin or pembrolizumab in recurrent or metastatic cervical cancer: 5-year results from the innovaTV 205/ENGOT-cx8/GOG-3024 study},
  author = {Els Van Nieuwenhuysen and Ignace Vergote and Leslie M. Randall and Jacqueline Tromp and Domenica Lorusso and Roisin E. O’Cearbhaill and Ingrid Boere and Carmela Pisano and Luis Manso Sanchez and Susana Banerjee and Dearbhaile C. Collins and Michal Zikán and Cara Mathews and Jan Kümmel and Bohuslav Melichar and Amanda L. Jackson and Kristine Madsen and Christine Gennigens and Nelleke Ottevanger and Sharad Ghamande and Vanda Salutari and Jean-Francois Baurain and Anna K.L. Reyners and Michael Chisamore and Umberto Conte and Kristian Windfeld and Melissa Geiger and Henrik Hansen and Hannelore Denys and David Cibula and Ana Oaknin and Toon Van Gorp and Bradley J. Monk},
  year = {2026},
  journal = {Gynecologic Oncology},
  doi = {10.1016/j.ygyno.2026.02.008},
  url = {https://doi.org/10.1016/j.ygyno.2026.02.008}
}

RIS

TY  - JOUR
TI  - Tisotumab vedotin plus carboplatin or pembrolizumab in recurrent or metastatic cervical cancer: 5-year results from the innovaTV 205/ENGOT-cx8/GOG-3024 study
AU  - Els Van Nieuwenhuysen
AU  - Ignace Vergote
AU  - Leslie M. Randall
AU  - Jacqueline Tromp
AU  - Domenica Lorusso
AU  - Roisin E. O’Cearbhaill
AU  - Ingrid Boere
AU  - Carmela Pisano
AU  - Luis Manso Sanchez
AU  - Susana Banerjee
AU  - Dearbhaile C. Collins
AU  - Michal Zikán
AU  - Cara Mathews
AU  - Jan Kümmel
AU  - Bohuslav Melichar
AU  - Amanda L. Jackson
AU  - Kristine Madsen
AU  - Christine Gennigens
AU  - Nelleke Ottevanger
AU  - Sharad Ghamande
AU  - Vanda Salutari
AU  - Jean-Francois Baurain
AU  - Anna K.L. Reyners
AU  - Michael Chisamore
AU  - Umberto Conte
AU  - Kristian Windfeld
AU  - Melissa Geiger
AU  - Henrik Hansen
AU  - Hannelore Denys
AU  - David Cibula
AU  - Ana Oaknin
AU  - Toon Van Gorp
AU  - Bradley J. Monk
PY  - 2026
JO  - Gynecologic Oncology
DO  - 10.1016/j.ygyno.2026.02.008
UR  - https://doi.org/10.1016/j.ygyno.2026.02.008
ER  -

APA

Nieuwenhuysen, E. V., Vergote, I., Randall, L. M., Tromp, J., Lorusso, D., O’Cearbhaill, R. E., Boere, I., Pisano, C., Sanchez, L. M., Banerjee, S., Collins, D. C., Zikán, M., Mathews, C., Kümmel, J., Melichar, B., Jackson, A. L., Madsen, K., Gennigens, C., Ottevanger, N., Ghamande, S., Salutari, V., Baurain, J., Reyners, A. K., Chisamore, M., Conte, U., Windfeld, K., Geiger, M., Hansen, H., Denys, H., Cibula, D., Oaknin, A., Gorp, T. V., & Monk, B. J. (2026). Tisotumab vedotin plus carboplatin or pembrolizumab in recurrent or metastatic cervical cancer: 5-year results from the innovaTV 205/ENGOT-cx8/GOG-3024 study. Gynecologic Oncology. https://doi.org/10.1016/j.ygyno.2026.02.008

Source records

crossref · retrieved 2026-09-26T06:00:49.590Z